In both mouse models and human breast cancer tissues, HELA‐Exos was shown to promote the activation of cDC1s, leading to an improvement in CD8+ T cell responses and the induction of immunogenic cell death (ICD) of tumor cells. The gene discussed is CD8A; the disease is neoplasm.